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Abstract
Hepatocellular carcinoma (HCC) incidence is growing among general population 
and especially in elderly patients. Recent development in surgical technique, surgical 
equipment, interventional radiology, and radiotherapy (hadrontherapy) allows us to 
use different techniques and approaches in order to treat this cancer. Patients are con-
ventionally considered disease-free after a 10-year recurrence-free period. Commonly, 
patients remain into a lifelong follow-up and recurrences are treated as they show. In 
this chapter, we will give description and indications of different curative techniques, 
especially hepatic resections and Radio-frequency thermal ablation (RFTA). We will 
also describe and give indications to palliative care techniques such as transarterial che-
moembolization (TACE), Selective Internal Radio-Therapy (SIRT), hadrontherapy, and 
supportive care. The aim of this chapter is to give information to clinicians and special-
ists dealing with the disease about the most effective approach to treat HCC, taking 
into account not only biological age, but also “physiological age,” performance status, 
comorbidities, and number of liver operative treatments. This chapter highlights that 
patients advanced in age are in particular need of a tailored medicine, where benefits 
are well weighted against invasivity of treatment and its side effects, in spite of assuring 
the best QoL and survival.
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1. Introduction
Hepatocellular carcinoma (HCC) is characterized by high clinical and biological variability 
[1]. Diagnosis and treatment of HCC always require multidisciplinary approaches.
Treatment requires commonly to make a decision between several specific interventions and 
to choose the one that allows the best risk-benefit ratio for a chosen patient.
Therapeutical approach shall take into account acute cirrhotic impairment risk and patient 
management experience, thus to avoid iatrogenic prognosis worsening.
Nowadays, patients older than 75 years account for 22% of HCC patients [2]. That is due 
to treatment and technological advancements which allow to reach an overall survival of 
decades, if therapy is well pondered; patients are kept in lifelong follow-up and intervention 
is timed well.
Therapeutical approaches to treat HCC can be divided into surgical approaches, such as major 
hepatic resection, minor hepatic resection, and wedge resection. Nonsurgical approaches are 
interventional radiology, chemotherapy, and most recently hadrontherapy. Since people 
older in age frequently have several comorbidities, often a specific less invasive therapeutical 
approach is needed.
Age is not a good outcome predictor: fit elderly patients may tolerate radical and invasive 
approaches, while unfit patients may not [3]. Treatment of older adults must take into account 
multiple issues related to the condition of aging itself. First of all, patient’s frailty, thus inva-
sive approaches are commonly excluded in patients advanced in age; on the other hand, 
noninvasive treatments are often palliative and do not achieve a satisfactory disease-free sur-
vival (DFS) or long-term survival (LTS) [3, 4]. Into this complex scenario, treatment strategies 
should also consider obstacles to cure the patients either physical or psychological, illness 
awareness, linguistic or cultural barriers, poverty, depression, and family environment.
Giving indication for or against invasive treatments is arduous in elderly. A decision for 
intervention shall consider either oncological principles and radical excision on one side or 
performance status, tolerability of treatment, and actual life expectancy on the other. HCC 
patients are not only in need for specific treatments, they must also be guided through routine 
activities in order to ameliorate their own hepatopathic condition, such as lifestyle correction 
(diet, water and salt assumption, physical activity, and smoking); instructions to the patient 
himself and to his family for therapeutical adhesion and instruction for early recognition of 
cirrhotic impairment or therapeutical side effects.
Physiological age is a new fundamental concept which is crucial in evaluating an advance in 
aged patient’s performance status beyond his chronological age, which is still today too often 
used as a threshold to exclude or include a patient into specific treatment protocols [4].
The aim of this chapter is to give guidelines about management of elderly patients suffering 
from HCC and to give indications to treat those suffering from HCC as primary malignancy, 
recurrent illness, or metastatic disease either.
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2. Patient management
2.1. Epidemiology and risk factors
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third 
most common cause of cancer mortality. In almost all populations, males have higher liver 
cancer rates than females, with male/female ratios usually averaging between 2:1 and 4:1 [1, 2].
HCC global distribution varies by region, incidence rate, sex, and also, by etiology. Normally, 
HCC incidence in female peaks 5 years later than males. Age-specific onset patterns are likely 
related to differences in the dominant hepatitis virus in population, age at viral infection, and 
the existence of other risk factors. As for average age at infection, normally, HCV carriers 
became infected in adulthood, while HBV carriers tend to become infected in childhood [2].
Recently, a significant increase in HCC incidence in hepatitis-free patients was noted; this 
index had a boost and went from 22% in 2000–2004 to 31% in 2010–2014 (database ITALICA) 
[5]. Among nonvirus-related hepatopathy, incidence of HCC in Alcoholic fatty liver disease 
patients (AFLD-patients) remains stable (17 vs. 19%), while a significant incidence increase 
was seen in Non Alcoholic fatty liver disease Patients (NAFLD-Patients) or in patients suffer-
ing from cryptogenic cirrhosis (0.5 vs. 9%) [5].
Often NAFLD-patients are demanding to treat; patients in this group have commonly several 
comorbidities such as metabolic syndrome; therefore, they need a more accurate and mul-
tidimensional clinical evaluation in order to choose the best treatment and achieve the best 
outcome from their condition.
HCV interferon-mediated clearance, associated with mild to severe fibrosis reduces hepa-
topathy progression and cirrhosis incidence, thus HCC’s incidence reduction in SVR patients 
is expectable.
HCC hazard in HBV replication-controlled infection is reduced but not abolished, although 
effective antiviral therapy reduces HCC incidence in HBV- or HCV-positive patients [6].
Sudden HCC recurrence was reported by several papers after Direct Acting Antiretrovirals 
(DAA) mediated HCV clearance [7]. Other papers have found similar incidence of HCC after 
DAA-mediated HCV clearance when compared to IFN-mediated SVR but considering an 
overall 24-month follow-up [7]. HCC incidence after HCV clearance is still not sufficiently 
evaluated.
2.2. Elderly management and evaluation
More than two-third of patients newly diagnosed with HCC are aged >65 years [8], and this 
number is expected to increase as the world population ages. Furthermore, there is hetero-
geneity in the aging process, which further contributes to the complexity of treatment deci-
sions. These factors contribute to age-related variations in treatment patterns and outcomes, 
potentially resulting in increased likelihood of under- or overtreatment, which can influence 
both risk of treatment toxicity and survival [9].
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Geriatric patients may be extremely complex to treat due to comorbidities that may affect them. 
Therefore, a clinical evaluation is fundamental to assess the best treatment for each patient.
Aspects that must be considered comprehend not only biological age, HCC stage, and liver 
status, but also general patient conditions, performance status, and, in particular, individual 
and familial psychological frame, will to fight against the disease, and treatment tolerabil-
ity. All these parameters are included into the concept of physiological age which goes far 
beyond chronological age and considers many crucial aspects of aging which is an extremely 
individual process.
Since chronologic age alone is a poor descriptor of heterogeneity in the aging process, a sys-
tematic and evidence-based way to assess physiological age is needed to guide treatment 
decisions.
Comprehensive geriatric assessment (CGA) is defined as a multidimensional, interdisciplin-
ary diagnostic process focusing on determining an older person’s medical, psychosocial, and 
functional capabilities to develop a coordinated and integrated plan for treatment and long-
term follow-up [10] (Table 1).
Important reasons to perform GA in older patients with cancer are detection of unidentified 
problems and risks for which targeted interventions can be applied and prediction of adverse 
outcomes (e.g., toxicity, other relevant items such as functional or cognitive decline, postop-
erative complications); and better estimation of residual life expectancy and lethality of the 
malignancy in the context of competing comorbidities and general health problems. There is 
Table 1. Considered parameters in Comprehensive geriatric Assessment.
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clear evidence that GA items independently predict OS in a variety of oncology diseases and 
treatment settings. Poorer OS in older patients with cancer and deficits identified in geriat-
ric domains might potentially be explained by several factors (e.g., increased risk of death 
resulting from causes other than cancer, increased death resulting from cancer because of less 
aggressive treatment, or death resulting from complications of cancer treatment) [9].
Patients with risk factors, in particular if older in age, must be lifelong under clinical surveil-
lance for HCC onset. Principal conditions that require normally a twice per year follow-up 
are advanced cirrhosis, active HCV infection or cleared HCV infection, and HBV-controlled 
infection. Surveillance is made by liver-US and serum α-fetoprotein assessment. Oncological-
marker-only surveillance is not recommendable and since cirrhotic parenchyma is on average 
poorly explorable, imaging shall be performed by a hepatobiliary dedicated team. Suspect 
nodules shall be further investigated by CT scan or hepatospecific MRI, which allows to make 
in the same session either a noninvasive diagnosis or staging when nodule is >10 mm in diam-
eter [11]. Noninvasive diagnosis is cost-effective and a big advantage especially for elderly in 
poor performance status.
Patients older in age are the cohort that receives the highest benefit in early cancer detection 
since lower stage HCCs are associated with less invasive interventions, faster recovery, lower 
mortality rate, and better QoL [4].
Therefore, geriatric patients shall be educated to strictly comply to follow-up timing and to 
change their lifestyle in order to ameliorate liver function and reduce liver damage.
HCC shall never be considered as a single-cell malignancy: it is a whole organ malignancy; cell 
transformation is due to liver damage from hepatotropic viruses, toxins, and metabolic syn-
drome [2, 4]. Even a radical liver resection that cures the single malignancy does not exclude 
the onset of further lesions and rarely metastases after radical resection is possible [12].
The aim of HCC treatment is to freeze the disease into a chronic stage and to treat lesions 
as they show. There are several possible treatments that allow in some cases extremely long 
survival, even in metastatic patients [12].
Management of HCC patients can be extremely complex, so only dedicated multidisciplinary 
teams shall treat these patients who are regularly discussed into liver units [4].
3. Surgical therapy
3.1. Hepatic resection
Hepatic resection is the gold standard in noncirrhotic liver. In western countries, HCC inci-
dence is raising, mostly due to NAFLD and metabolic syndrome [13].
Patients with these pathologic conditions can develop HCC in the absence of cirrhosis or 
severe fibrosis [14], although hepatic parenchyma shall not be considered healthy since 
steatosis is determinable in 50% of patients and steatohepatitis (NASH) in 25% [15, 16]. A 
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multicentric study confirmed that HCC patients suffering from metabolic syndrome have 
higher postoperative hepatic failure, mortality, and morbidity rates [15, 16].
Nevertheless, hepatic resection on metabolic syndrome-liver has excellent oncologic effective-
ness and leads to long-time survival [16].
In cirrhotic patients, hepatic resection is the first-line treatment for single HCC nodule and 
preserved hepatic function, strict indications for hepatic resection are serum-bilirubin <1.5 mg/
dl and Hepatic Portal-Venous Gradient (HPVG) ≤10 mmHg or platelets ≥100,000 [17].
Resection in patients with light portal hypertension and nonenrollable for liver transplant 
shall be well weighted against locoregional treatments [17].
Cirrhotic liver resection can be a safe practice in well-selected patients with low morbidity 
and mortality rates [18]. Selection shall be lead through a global, multiparametric evaluation 
of the patient and shall pass beyond a dogmatic data interpretation.
All guidelines agree that is needed to select cirrhotic patients for hepatic resection thus to 
achieve the best outcome, but selection criteria are not universally accepted, the ones sug-
gested from several surgical groups are not based on strong evidence. Therefore, it is neces-
sary to develop a multiparametric evidence-based prognostic score to allow to evaluate a 
“tailored” operative risk and expected survival.
Tailored-risk evaluation is even more important in elderly patients since aging is a strict-
individual process, multidimensional evaluation, and CGA score, in particular, are crucial to 
assess whether advanced in aged patients can be either enrolled or not for surgery with a deep 
gap in quality of life and overall survival [4].
Child-Pugh class B patients are routinely excluded from surgery; however, in some cases, satisfy-
ing outcome was achieved by performing limited hepatic resections in strictly selected patients, 
with mild serum bilirubin raise (≤2 mg/dl) and without portal hypertension [19] (Table 2).
Laparoscopic or robotic approaches could widen indications to Child-Pugh class B patients 
due to their little invasivity.
In elderly patients, these approaches are extremely interesting.
Table 2. Indications to liver resection in HCC patient.
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Hepatic surgery obtains excellent results in elderly patients, even if cirrhotic. Advance age 
alone is no more a contraindication to surgery.
However, elderly patients, cirrhotic or not, are often excluded from surgery due to comor-
bidities that rise ASA score and operative risk. Mini-invasive procedures on the one hand 
make operative time longer and worsen blood-gases control; on the other hand, they allow 
to spare hepatic parenchyma and shorten hospitalization and recovery [20]. Therefore, 
patients treated with mini-invasive surgery vs. open achieve a better outcome, especially 
if elderly, who often suffer longer hospitalizations either physically (reduced physical 
activity and nosocomial infection risk) and psychologically (depression, confusion, and 
dizziness) [20].
As reported by a recent meta-analysis, even better outcome is achieved with surgery (open or 
mini-invasive) vs. transarterial chemoembolization (TACE), which is the most used palliative 
care technique for HCC, whose advantage remains consistent even in advance HCC, even if 
vascular invasion is present, so up to stage Barcelona Clinic Liver Cancer (BCLC) stageC [17, 21].
Portal hypertension is often associated with hepatic damage. However, several studies proved 
that hepatic residual functionality and not portal hypertension affects short- and long-time 
outcome of hepatic resections [22, 23].
Patients with mild portal hypertension and preserved hepatic functionality can receive limited 
resections with morbidity, mortality, and OS similar to patients without portal hypertension [19].
HCC frequently develops and spreads through the portal system and that is why several 
authors recommend performing anatomical resections; these studies prove a better OS and 
local disease control for anatomic resection vs. wedge resection [24, 25].
More recently, a large Japanese retrospective study (more than 72,000 patients) proved supe-
riority of anatomical resection only for HCC diameter >2 and <5 cm. Superiority is not proven 
if HCC diameter is <2 cm since portal diffusion risk is very low or >5 cm because other factors 
influence prognosis [26].
It is also possible to match a parenchyma-sparing surgery with anatomical resection, thanks 
to subsegmental US-guided resections [27]. This technique with laparoscopic subglissonian or 
extraglissionan approach is not of common use, due to its technical difficulty and exclusion crite-
ria, that are ascites and moderate to severe portal hypertension. The approach remains interesting 
and future technical development is possible, especially thanks to robotic surgery. Subsegmental 
resection shall not be performed for advanced HCC (diameter >2 cm) in order to respect onco-
logic principles of a radical resection [27]. The procedure allows to spare liver parenchyma, and it 
may be really interesting for elderly even if cirrhotics with an early-HCC diagnosis.
3.2. Liver transplantation
Liver transplantation (LT) is considered the first-line treatment for cirrhotic patients. LT indi-
cations are given following the Milan criteria: single HCC nodules (diameter <5 cm) or less 
than 3 HCC nodules all <3 cm and in any case nonresectable [17].
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A modest expansion to Milan criteria was given by “up to seven criteria,” which had achieved 
satisfactory results in patients without extrahepatic metastases and/or macrovascular inva-
sion. A prospective validation is needed [28].
An increasing number of older patients with end-stage liver disease (ESLD) are evaluated for 
liver transplantation (LT). In fact, patients aged ≥65 years represent one of the fastest-growing 
patient populations in LT [29]. The most extreme of these patients, those aged ≥70 years, are 
associated with several difficult clinical dilemmas. Firstly, advanced patient age is associated 
with higher risk and poorer outcomes after complex surgical procedures [30]. LT in advanced 
age patients is associated with increased risk for infection and cardiovascular impairment, 
increased resource utilization, and lower patient survival [31]. Since the number of adult can-
didates on the waiting list continues to rise and organ availability remains unable to fully 
meet this demand, proper organ allocation and utilization are critically important.
Equivalent outcomes can be achieved in elderly recipients and age alone should not be used 
as a barrier to LT.
Recent data for waitlist registrants on the SRTR registry suggest that <12% of waitlisted 
patients are aged ≥65 years, but this proportion has steadily increased over the past decade. 
Continued improvements in care in pre- and posttransplant medicine and surgery suggest 
that this age group will continue to grow on the waiting list. With this demographic shift in 
the ESLD, more elderly patients will be considered for LT, and the use of scarce donor livers 
will need to be addressed because these recipients have a shorter life expectancy compared 
with younger patients. Despite the shortened lifespan, single-centered reports have shown 
equivalent posttransplant survival in super-selected patients [32, 33].
Due to physical and psychological impairment, elderly patients are often considered unfit for 
liver transplantation, since in super-selected groups only satisfying result in LT is achieved, 
surgical resection remains, for elderly, the first-line approach when performable.
4. Nonsurgical therapies
4.1. Intervention radiology
4.1.1. Radiofrequency thermoablation and microwave thermoablation
Percutaneous radiofrequency thermoablation (RFTA) and microwave thermoablation (MWA) 
are considered the standard care for patients with BCLC 0-A HCC, who are not eligible for 
surgical treatment.
Percutaneous ablation techniques are indicated for HCC nodules <2 cm, while nodules with 
diameter between 2 and 3 cm need to be discussed in a multidisciplinary unit in order to 
determine an appropriate management plan (Table 3). In patients with a single HCC nodule 
less than 2 cm in diameter, a complete necrosis ratio of 97% is expected [34].
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Several randomized studies have documented the superiority of surgical resection over per-
cutaneous ablation techniques in terms of efficacy, while thermoablation has shown lower 
morbidity, mortality, hospitalization rates, and costs [35].
MWA and RFTA have shown comparable safety and effective results, although MWA 
seems to have certain theoretical advantages compared to RFTA: shorter procedure, higher 
ablation temperature, larger area of necrosis, lower probability of biliary duct injury, and 
reduction in the heat-sink effect through a more uniform heating in the volume of abla-
tion. However, these advantages have not been confirmed in clinical practice. Although 
EASL guidelines recommend the use of MWA for nodules up to 4 cm, a recent phase II 
trial, comparing the two techniques in patients with similar mean lesion volumes, showed 
no significant difference between them in terms of outcome and recurrence ratio [36].
RFTA and MWA can also be safely and effectively performed via a video laparoscopic (VL) 
approach [37]. VL allows the operator to treat nodules that would normally not be eligible for 
a percutaneous approach due to nonaccessible locations and allows for hybrid management 
of patients with multiple nodules (e.g., surgical resection and RFTA on additional nonresect-
able nodules).
Percutaneous ablation techniques are a precious tool in management of elderly patients with 
multiple comorbidities.
HCC is often methacronous and new nodules are expected to develop during follow-up after 
the first tumor. Therefore, it is crucial to perform an appropriate follow-up in patients who have 
been treated for HCC, in order to detect new nodules at an early stage, so that the least invasive 
treatment available can be delivered. This is particularly relevant in elderly patients, or those 
who have already undergone extensive hepatic resection, who might not be eligible for surgery.
Percutaneous ablation is a recommended treatment modality, when indicated, due to its 
mini-invasive nature, high effectiveness, low rates of adverse events, short hospitalization 
times, and its relatively few contraindications.
4.1.2. Transarterial chemoembolization
Transarterial chemoembolization (TACE) is a palliative treatment that is routinely used in 
patients with HCC that are neither eligible for surgery nor for percutaneous ablation, and in 
Table 3. Indications to Radio-Frequency Thermal Ablation.
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stage BCLC B HCC. TACE is indicated for asymptomatic patients in Child-Pugh class up to 
B7 and PS ≤ 1 [17] (Table 4).
A study found no significant difference in survival following TACE in patients with Child-
Pugh Class 8–9 compared to class 7; however, patients with Child-Pugh 8–9 had a significant 
worse prognosis and more dangerous side effects [38].
TACE is not indicated for patients with signs of HCC vascular invasion, metastases, untreat-
able ascites, jaundice, thrombosis of a major portal vessel, and HCC nodules >10 cm. In these 
cases, due to an already compromised liver function, there is a high risk of liver failure and 
eventually death.
Drug-eluting beads TACE (DEB-TACE) is a more recent variation of conventional TACE 
(cTACE) that uses embolizing beads eluted with doxorubicin as a chemotherapeutic agent. 
It has shown overall similar effectiveness, but less systemic side effects compared to cTACE.
Randomized trials have found superior outcomes with DEB-TACE compared to cTACE in 
patients with Child-Pugh class B and/or PS ≥ 1 [39, 40].
Although contrast-enhanced CT (CECT) or MRI with hepatospecific contrast agent is recom-
mended for TACE outcome evaluation, contrast-enhanced US (CEUS) could be an appropri-
ate alternative in patients with less than four nodules [41].
If imaging follow-up detects residual or recurrent HCC nodules, TACE can be repeated 
up to three times per nodule. Treatment failure is considered when there are no signs of 
lesion response, as assessed using the mRECIST criteria, after two treatments or if there is no 
complete response after three treatments [42]; in eastern countries, different staging criteria, 
RECICIL, are actually in use [43].
TACE has been proved safe and effective in elderly as well as in younger patients. In particu-
lar, a prospective study found that elderly patients suffered from the same complication rates 
as nonelderly, while effectiveness rates were similar [44].
More important than age is the liver functional status, and the patient’s performance status 
that mostly affects the safety profile of TACE. Therefore, TACE can be an effective palliative 
treatment able to give benefits in terms of disease control and improved quality of life in 
elderly patients with HCC.
Table 4. Indications to Trans Arterial Chemo-Embolization.
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TACE can also be combined with percutaneous ablation, particularly in patients with tumor 
recurrence within 1 year since the initial treatment, those with tumor diameters of 3.1–5.0 cm, 
and those with tumor recurrences after initial treatment with thermoablation, where sequen-
tial TACE-thermoablation might be the best treatment option [45].
The benefit of this sequential approach is due to the occlusion of hepatic arterial flow by 
means of embolization before ablation. Furthermore, lipiodol and gelatine sponge particles 
used in TACE reduce the portal flow around the tumor by filling the peripheral portal vein via 
multiple arterioportal communications. Therefore, the reduced cooling effect of the hepatic 
blood flow on ablation-induced thermal coagulation allows the achievement of an enlarged 
ablation zone which might reduce recurrence rates.
4.1.3. Transarterial radioembolization
Transarterial radioembolization (TARE) is a palliative brachytherapy for HCC. Radioactive 
substances (I131-lipidol or Y90-beads) are delivered into the tumor by injecting them selec-
tively into its feeding arteries.
This is a complex technique that requires a high-level specialization and has potentially severe 
side effects such as hepatic, intestinal, and lung toxicity [17]. Therefore, it should only be per-
formed in specialized centers, with high volume activity and experience with this procedure.
Given the fact that TARE has minimal embolizing effects, it can be safely performed even in 
patients with thrombosis of the portal vein or its branches.
It can be used as a first-line treatment when TACE is not recommended, such as in the case 
of large or multifocal HCC or if there are signs of portal thrombosis. However, liver function 
must be conserved (Child-Pugh ≤7, bilirubin ≤2.0 mg/dl, no ascites) [17].
TARE has also been shown to be an appropriate bridge or downstaging treatment in order to 
meet liver transplantation criteria [17, 46].
Furthermore, TARE can be used as a second-line treatment in patients who did not respond 
to TACE or who are intolerant to chemotherapy [17, 47].
Mean survival for Child-Pugh class A or B patients who underwent TARE is, respectively, 17.2 
and 7.7 months [48, 49]. Mean survival for patients with portal vein thrombosis is 9 months, 
while for those with intrahepatic portal thrombosis is 17 months [50].
A study has revealed similar results in terms of overall survival (OS) and toxicity between 
cTACE and TARE in patients with nonresectable HCC [51]; another study has shown a better 
time-to-progression (TTP) and lower toxicity following TARE compared to TACE [52].
TARE cannot be performed in patients with a pulmonary shunt >20% or if other vascular 
anomalies may cause irradiation of visceral organs (stomach and intestine) [17].
Indications for this treatment are often controversial and should only be discussed in dedicated 
multidisciplinary teams. The difficulty in determining the precise indications of TARE is in 
part due to the lack of cost-effectiveness studies and the fact that its therapeutical equivalence 
to TACE has only been proved in selected patients. TARE is usually indicated in patients with 
stage BCLC C HCC, especially those with portal vein thrombosis and preserved liver function.
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TARE is usually not indicated in elderly patients, who often have a compromised liver func-
tion, and therefore, risks of liver failure and death are high. TARE can be performed in elderly 
with good performance status and liver functionality as a second-line treatment in patients 
with treatment failure following TACE.
TARE has not been shown superior to sorafenib in treating advanced HCC; therefore, 
sorafenib could be a safer treatment in elderly patients who can tolerate chemotherapy [53].
4.1.4. Other
4.1.4.1. Percutaneous ethanol injection (PEI)
PEI induces cell necrosis through dehydration, protein denaturation, and small vessel disrup-
tion. It is not often used since it can only be performed in lesions <2 cm and it has a higher 
recurrence ratio than percutaneous ablation. It has indication only in lesions that are not con-
sidered safe for ablation due to their localization [54].
Compared to PEI, RF has shown better outcomes in terms of overall survival, survival at 1, 
2, and 3 years, and cancer-free survival at 1, 2, and 3 years. This is probably due to the better 
performance of RF in terms of complete necrosis of the lesion and the low percentage of local 
recurrence [54].
RF requires fewer treatment sessions and shorter hospitalization than ethanol injection: 
although the quality of life of these patients was not evaluated, there was a decrease in hos-
pitalization rates [54].
4.1.4.2. Cryoablation
Cell death with cryoablation is different than that with thermal ablation. The freezing process 
results in both intracellular and extracellular ice formation, both of which can result in cel-
lular death, but by different mechanisms. Since the ablation zone is reperfused after the ice 
ball melts, the result is a rapid release of cellular debris into the systemic circulation. This 
probably explains the systemic complications of cryoablation (i.e., cryoshock) that are rare 
with heat-based ablation. Thermoablation is the preferred ablation method for treating HCC 
in patients with cirrhosis because of the increased risk of bleeding and of disseminated intra-
vascular coagulation-like reaction (called cryoshock) associated with cryoablation [55, 56]. 
Therefore, although many studies have shown that small-volume cryoablation is feasible in 
patients with cirrhosis and HCC, it is difficult to justify the additional risk of cryoablation in 
these patients when viable heat-based alternatives are available [55].
4.1.4.3. Laser ablation (LA)
The term laser ablation refers to the thermal tissue destruction by conversion of absorbed light 
(usually infrared) into heat. Infrared energy penetrates tissue for 12–15 mm in depth; heat is 
conducted beyond this range thereby creating a larger ablation area. Optical penetration has 
been shown to be increased in malignant tissue compared to normal parenchyma [57].
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Local tissue properties, in particular perfusion, have a significant impact on the size of the 
ablation zone. Highly perfused tissue and large blood vessels act as a heat sink, since infrared 
energy is absorbed by erythrocytic heme and transported away from the target area. This 
phenomenon makes normal liver parenchyma relatively more resistant to LA than tumor 
tissue and this is the rationale for using hepatic inflow occlusion techniques such as arterial 
embolization (TACE) in conjunction with laser therapy [57].
Light transmission into tissues and the size of the ablation zone increase with higher laser 
power, as does the local tissue temperature reached during ablation, with consequent higher 
risk of overheating and carbonization of the adjacent normal tissue.
The use of water-cooled laser application sheaths allows the use of a higher laser power out-
put while preventing carbonization [58]. When using multiple water-cooled higher power 
fibers, ablation zones of up to 80 mm diameter can be obtained.
Major complications of LA are liver failure, segmental infarction, hepatic abscess, cholangitis, 
bile duct injury, and hemorrhage. The technique is considered safe by rates of 1.8% for major 
complications and a mortality rate of 0.1% [59] and can also be used safely in elderly patients 
with advanced liver disease up to Child–Pugh class B [57]. Tumor seeding after percutaneous 
biopsy and ablative therapies is a well-known phenomenon, but it has rarely been reported 
following laser ablation [57].
A recent study compared LA and TACE in patients with a single large HCC and found a 
significant superiority in multifiber-LA vs. TACE in terms of recurrence rates, especially in 
nodules >4 cm, while OS was similar between both groups [60].
Ablation size is critical to predict outcome; patients with lesions >6 cm or with multifocal 
disease (more than five nodules) are usually managed with other treatment modalities.
LA can be used with a curative intent only in patients with early-stage HCC. In this setting, it 
has shown similar outcomes compared to RFTA when treating nodules <3 cm [57, 60].
In patients with advanced local HCC, LA should only be used as a palliative treatment. The 
use of laser ablation is not currently extensively adopted for the treatment of HCC, but given 
the promising outcomes shown in recent studies and the expected technical advancements, it 
could become an increasingly more important treatment modality for HCC in the near future.
4.2. Chemotherapy
Systemic therapy is recommended for HCC patients in stage BCLC-C with conserved liver 
functionality (Child-Pugh A), good performance status, advanced disease, and/or extrahe-
patic diffusion. Systemic therapy is also recommended for patients with progressive HCC 
after locoregional treatments or HCC with vascular invasion not enrollable for other local 
treatments [17].
Target therapy with sorafenib proved to give survival benefits versus either placebo or cyto-
toxic and hormonal therapy [61].
Observational studies suggest that sorafenib administration in Child-Pugh B patients is as 
safe as administration in class A patients [62].
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Recently, RESORCE trial showed survival benefit in regorafenib administration vs. placebo 
for HCC patients that went to tumor progression after sorafenib administration; all patients 
had tyrosine kinases-associated adverse effects [63].
Cytotoxic chemotherapy, such as doxorubicin or FOLFOX4 scheme, can be considered in 
patients with conserved liver functionality and after that sorafenib therapy has suspended for 
adverse effects [17] (Table 5).
Adverse effects of sorafenib especially dermatological, hypertension, or diarrhea in the first 
month of treatment are a frequent cause of treatment failure; it was proved that half-dose 
administration after adverse effects is associated with survival benefits [64].
In some cases, for fit and super-selected patients, intolerant to sorafenib, in case of oligometa-
static disease, a different disease management can be done. Mini-invasive surgical therapy 
along with intervention radiology may be able to remove several metastases and treat them 
as they show; once the primitive tumor is surgically resected, a chronic metastatic disease 
can be surgically controlled with survival benefits [12]. Only case reports on this field have 
been published, but these authors believe that more research shall be done with multicentric 
clinical trials to prove what has been shown only in case reports.
Elderly can hardly ever be treated with surgical therapy due to their frailty and low PS 
even if in many cases, biological age does not correspond to chronological age. Sorafenib 
showed similar results in terms of safety and effectiveness in elderly and younger HCC 
populations. When administering systemic therapy, careful baseline evaluation is needed 
for patient’s selection in elderly population, including discussion about antiplatelet 
therapy discontinuation, and caution in PS ≥ 1 patients, as well as active management of 
toxicity.
Asthenia and bleeding are more frequent in the elderly. The higher frequency of bleeding is 
explained by concomitant antiplatelet treatments, and major asthenia is frequent in PS ≥ 1 
elderly patients [65].
A multidimensional evaluation is crucial for elderly patients and also in advanced HCC, and 
decision to start systemic therapy shall be made by experienced and dedicated units.
Table 5. Most common adverse effects of Sorafenib.
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4.3. Best supportive care
Palliative treatments and supportive care aim at ameliorating patients QoL and at giving 
relief by symptoms. Terminal-stage HCC may have several symptoms associated with liver 
dysfunction due to cirrhosis, such as ascites, esophageal hemorrhage, and hepatic encepha-
lopathy. Abdominal pain and asthenia are common.
Paracetamol and opioids are the safest drugs for pain control in hepatopathics; Non Steroideal 
Antinflammatory Drugs (NSAIDs) shall be avoided due to hemorrhage risk, kidney dysfunc-
tion risk, and resistant ascites development.
Radiotherapy is effective in pain control due to bone metastases; control results complete in 
50% of patients and partial in 80–90% [66].
Percutaneous cementoplasty is effective in controlling HCC vertebral metastases’ pain [67]. 
Brain metastases are rare and selected cases can be treated with stereotaxic radiotherapy [68].
Malnutrition and cachectic-state is common in end-stage oncological patients, in particular 
if affected by noncontrolled cirrhosis which enhances weight loss and muscular tissue loss.
Nutritional state assessment is important in HCC patients and was observed that prognostic 
nutritional index can predict survival expectancy in HCC patients [69].
4.4. Frontiers in palliative treatment of HCC: hadrontherapy
Hadrontherapy or heavy charged particle therapy (CPT) is one of the newest palliative treat-
ments available against HCC.
Hadrontherapy technology is based on charged particles (carbon ions), which accelerated by 
cyclotrons or synchrotrons are conveyed into a beam to irradiate the tumor. Different from 
X-rays, charged particles have a sharp Bragg’s peak which is even sharper than the one of 
protons; therefore, they release a great part of their energy at a specific level of tissue penetra-
tion which is proportional to their kinetic energy.
This technology allows to concentrate cellular damage into a very small area; therefore, CPT 
has higher tumor control probability (TCP) and relative biological effectiveness (RBE) than 
other radiotherapy techniques, it can also reduce organs at risk (OAR) and nonmalignant 
tissue complications probability (NTCP) [70].
Due to the physical properties of charged particles and, in particular, the possibility to gener-
ate a heavy concentrated damage, hypofractioning is possible with good results in terms of 
adverse effects.
Clinical trials on CPT are still running; first data are hopeful; in a Japanese study that 
used CPT in nontreatable HCC, a 5-year local control rate was 81% and survival was 33%; 
results are similar to those for proton therapy with 20 fractions, but by using a total of 4 
fractions in 2 days [71]. Good results are also obtained with difficult to treat porta-hepatis 
HCC [69]. As for HCC metastases, they can be treated with a 50.4 Gy irradiation in 12 
fractions [12, 71].
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Figure 1. Summary—HCC treatment decision chart in elderly recipients.
These treatments are still experimental but results of trials until now are encouraging, in the 
next future hadrontherapy may be one of the pillaRs of advance HCC treatment.
Hadrontherapy may be extremely interesting as a treatment also for elderlies, since it has 
little adverse effect and thanks to hypofractioning and noninvasivity; in the future, it may 
become a treatment of choice for difficult-to-treat HCC in elderly and for metastatic disease. 
It may ensure long-time tumor control and good QoL even in people advanced in age; the 
only issue of this treatment is its high cost-effectiveness ratio, even though cost-effectiveness 
trials for CPT are not still published a CPT apparatus costs around US$ 200 million; only 
three carbon ion centers are available in Western Europe, seven in Asia (Japan and China), 
and none in US [65] (Figure 1).
5. Conclusion
The aim of this chapter is to give information and indications about the most recent operative 
and nonoperative existing techniques to treat HCC. Focus on older adults’ case evaluation is 
of extreme importance; because lifespan enlargement will produce, in next decades, a sharp 
rise in HCC incidence among elderlies [2].
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It is strongly believed, by this multidisciplinary team, that early diagnosis is the key for 
HCC eradication in general population and in particular in elderly: dealing with a lower-
staged cancer allows to use both less invasive and more radical treatments. Patients would 
then suffer less hospitalization time; would have faster recovery and lower infection risk 
[4]. Hospitalization time and subsequent infections are the most common cause of death for 
hospitalized elderly patients. Early-HCCs grow slowly when they develop in elderlies and 
when removed surgically or with interventional radiology mean (RFTA or MWA) recurrences 
appear after a sufficient time latency thus to make it possible to chronicize the disease and 
allow to reach survival rates not different from general population [4].
The elderlies are a very heterogenic population; therefore, this kind of patients cannot be 
treated with a standardized protocol, but a tailored approach is needed. Each patient has its 
own comorbidities that must be taken into account; moreover, aging itself is an extremely 
individual process and different patients may have wide differences in performance status 
and therefore different treatment indications. Life expectancy, comorbidities, liver functional-
ity, cancer progression, patient’s therapy compliance, psychological status, and performance 
status shall be all taken into account when cases are discussed into multidisciplinary teams in 
order to assure the best treatment, and therefore, the best OS and QoL.
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